{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:17:14Z","timestamp":1783667834248,"version":"3.55.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004695","name":"University of KwaZulu-Natal","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004695","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Broadly neutralising antibodies (bNAbs) represent a promising long-acting modality for HIV prevention. However, substantial interindividual pharmacokinetic variability poses a threat to real-world efficacy. This review investigates the impact of systemic inflammation, driven by the high prevalence of sexually transmitted infections (STIs), co-endemic pathogens, and metabolic activation, on bNAb persistence, particularly within the vulnerable demographic of women in sub-Saharan Africa. We aim to bridge the gap between neonatal fragment crystallisable receptor (FcRn) biology and clinical pharmacokinetic observations to identify why certain individuals clear bNAbs faster than others.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Synthesis of recent clinical trial data and cross-therapeutic PK evidence indicates that systemic inflammatory biomarkers are strong predictors of accelerated monoclonal antibody clearance. Recent evidence suggests that chronic inflammation modulates bNAb half-life through the transcriptional downregulation of the\n                      <jats:italic>FCGRT<\/jats:italic>\n                      gene, which encodes FcRn, and the competitive saturation of FcRn recycling pathways. These findings suggest that bNAbs\u2019 standard dosing does not account for the inflammatory burden that characterises many real-world populations, potentially leading to sub-therapeutic concentrations and an increased risk of breakthrough HIV infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The host\u2019s inflammation status is a primary and currently overlooked determinant of antibody pharmacokinetics. This review provides a roadmap to overcoming the pharmacokinetic heterogeneity modulated by systemic inflammation through establishing the link between inflammation and increased antibody clearance. Bridging these insights paves the way for effective bNAbs with promising implications for prospective HIV prevention and cure strategies that are not only effective in controlled clinical trials but also protective in real-world settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-026-00791-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:01:34Z","timestamp":1783666894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Inflammation as a Modulator of FcRn-dependent IgG Pharmacokinetics: Implications for Broadly Neutralising Antibody Efficacy in HIV Prevention"],"prefix":"10.1007","volume":"23","author":[{"given":"Andile","family":"Khumalo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjali","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivanka","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharana","family":"Mahomed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derseree","family":"Archary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"791_CR1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","volume":"28","author":"PB Gilbert","year":"2022","unstructured":"Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, Giorgi EE, Korber B, Edlefsen PT, Rossenkhan R, Juraska M, Rudnicki E, Kochar N, Huang Y, Carpp LN, Barouch DH, Mkhize NN, Hermanus T, Kgagudi P, Bekker V, Kaldine H, Mapengo RE, Eaton A, Domin E, West C, Feng W, Tang H, Seaton KE, Heptinstall J, Brackett C, Chiong K, Tomaras GD, Andrew P, Mayer BT, Reeves DB, Sobieszczyk ME, Garrett N, Sanchez J, Gay C, Makhema J, Williamson C, Mullins JI, Hural J, Cohen MS, Corey L, Montefiori DC, Morris L. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022;28:1924\u201332. https:\/\/doi.org\/10.1038\/s41591-022-01953-6.","journal-title":"Nat Med"},{"key":"791_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/337184a0","volume":"337","author":"NE Simister","year":"1989","unstructured":"Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337:184\u20137. https:\/\/doi.org\/10.1038\/337184a0.","journal-title":"Nature"},{"key":"791_CR3","doi-asserted-by":"publisher","unstructured":"Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, Gengiah T, Archary D, Samsunder N, Rose ND, Moore P, Williamson C, Barouch DH, Fast PE, Pozzetto B, Hankins C, Carlton K, Ledgerwood J, Morris L, Mascola J. Abdool Karim, Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: Study protocol for the first-in-human CAPRISA 012B phase i clinical trial. BMJ Open. 2020;10. https:\/\/doi.org\/10.1136\/bmjopen-2020-042247.","DOI":"10.1136\/bmjopen-2020-042247"},{"key":"791_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/infdis\/jiac041","volume":"226","author":"S Mahomed","year":"2022","unstructured":"Mahomed S, Garrett N, Capparelli EV, Osman F, Harkoo I, Yende-Zuma N, Gengiah TN, Archary D, Samsunder N, Baxter C, Mkhize NN, Modise T, Carlton K, McDermott A, Moore PL, Karim QA, Barouch DH, Fast PE, Mascola JR, Ledgerwood JE, Morris L. Abdool Karim, Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. J Infect Dis. 2022;226:510\u201320. https:\/\/doi.org\/10.1093\/infdis\/jiac041.","journal-title":"J Infect Dis"},{"key":"791_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, F\u00e4tkenheuer G, Schlesinger SJ, Nussenzweig MC. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487\u201391. https:\/\/doi.org\/10.1038\/nature14411.","journal-title":"Nature"},{"key":"791_CR6","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1038\/s41467-023-43399-5","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhang L, Karuna S, Andrew P, Juraska M, Weiner JA, Angier H, Morgan E, Azzam Y, Swann E, Edupuganti S, Mgodi NM, Ackerman ME, Donnell D, Gama L, Anderson PL, Koup RA, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Lemos MP. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01. Nat Commun. 2023;14:7813. https:\/\/doi.org\/10.1038\/s41467-023-43399-5.","journal-title":"Nat Commun"},{"key":"791_CR7","doi-asserted-by":"publisher","first-page":"13499","DOI":"10.1038\/s41598-024-63902-2","volume":"14","author":"P Sobia","year":"2024","unstructured":"Sobia P, Mahomed S, Sivro A, Paul S, Osman F, Harkoo I, Garrett N, Karim QA, Karim SSA, Archary D. Circulating immunoglobulins and transient lymphocytopenia in a sub-study of CAPRISA 012B, testing HIV monoclonal antibodies in a phase 1 trial. Sci Rep. 2024;14:13499. https:\/\/doi.org\/10.1038\/s41598-024-63902-2.","journal-title":"Sci Rep"},{"key":"791_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4161\/mabs.27765","volume":"6","author":"N Chen","year":"2014","unstructured":"Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. MAbs. 2014;6:502\u20138. https:\/\/doi.org\/10.4161\/mabs.27765.","journal-title":"MAbs"},{"key":"791_CR9","doi-asserted-by":"crossref","unstructured":"Liu X, Ye L, Bai Y, Mojidi H, Simister NE, Zhu X. Activation of the JAK\/STAT-1 Signaling pathway by IFN-\u03b3 can down-regulate functional expression of the MHC Class I-Related Neonatal Fc Receptor for IgG 1, 2008.","DOI":"10.4049\/jimmunol.181.1.449"},{"key":"791_CR10","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.4049\/jimmunol.179.5.2999","volume":"179","author":"X Liu","year":"2007","unstructured":"Liu X, Ye L, Christianson GJ, Yang J-Q, Roopenian DC, Zhu X. NF-\u03baB Signaling Regulates Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG via Intronic Binding Sequences. J Immunol. 2007;179:2999\u20133011. https:\/\/doi.org\/10.4049\/jimmunol.179.5.2999.","journal-title":"J Immunol"},{"key":"791_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/civ298","volume":"61","author":"L Masson","year":"2015","unstructured":"Masson L, Passmore J-AS, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q. Abdool Karim, Genital Inflammation and the Risk of HIV Acquisition in Women. Clin Infect Dis. 2015;61:260\u20139. https:\/\/doi.org\/10.1093\/cid\/civ298.","journal-title":"Clin Infect Dis"},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1186\/s12879-023-08736-5","volume":"23","author":"JM Gizamba","year":"2023","unstructured":"Gizamba JM, Davies J, Africa C, Choo-Kang C, Goedecke JH, Madlala H, Lambert EV, Rae DE, Myer L, Luke A, Dugas LR. Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: a systematic review and meta-analysis. BMC Infect Dis. 2023;23:861. https:\/\/doi.org\/10.1186\/s12879-023-08736-5.","journal-title":"BMC Infect Dis"},{"key":"791_CR13","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2666-5247(21)00037-9","volume":"2","author":"E Du Bruyn","year":"2021","unstructured":"Du Bruyn E, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tib\u00farcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe. 2021;2:e375\u201385. https:\/\/doi.org\/10.1016\/S2666-5247(21)00037-9.","journal-title":"Lancet Microbe"},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/microorganisms9040879","volume":"9","author":"S Qian","year":"2021","unstructured":"Qian S, Li C, Liu X, Jia X, Xiao Y, Li Z. Activation of the JNK\/MAPK Signaling Pathway by TGF-\u03b21 Enhances Neonatal Fc Receptor Expression and IgG Transcytosis. Microorganisms. 2021;9:879. https:\/\/doi.org\/10.3390\/microorganisms9040879.","journal-title":"Microorganisms"},{"key":"791_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7:192. https:\/\/doi.org\/10.1186\/s40425-019-0669-y.","journal-title":"J Immunother Cancer"},{"key":"791_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","volume":"5","author":"T Freshwater","year":"2017","unstructured":"Freshwater T, Kondic A, Ahamadi M, Li CH, de Greef R, de Alwis D, Stone JA. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017;5:43. https:\/\/doi.org\/10.1186\/s40425-017-0242-5.","journal-title":"J Immunother Cancer"},{"key":"791_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li C, de Alwis D, de Greef R, Elassaiss-Schaap J, Kondic A, Stone J. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6:49\u201357. https:\/\/doi.org\/10.1002\/psp4.12139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"791_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2014.42","volume":"3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin\u2019s Lymphoma and Exposure\u2013Response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014;3:1\u201311. https:\/\/doi.org\/10.1038\/psp.2014.42.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"7132","DOI":"10.3390\/jcm12227132","volume":"12","author":"T Deyhim","year":"2023","unstructured":"Deyhim T, Cheifetz AS, Papamichael K. Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics. J Clin Med. 2023;12:7132. https:\/\/doi.org\/10.3390\/jcm12227132.","journal-title":"J Clin Med"},{"key":"791_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, Math\u00f4t RA, Ponsioen CY, L\u00f6wenberg M, D\u2019Haens GRAM. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology. 2015;149:350\u2013e3552. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.016.","journal-title":"Gastroenterology"},{"key":"791_CR21","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.3390\/ijms26157274","volume":"26","author":"M Maksic","year":"2025","unstructured":"Maksic M, Corovic I, Maksic T, Zivic J, Zivic M, Zdravkovic N, Begovic A, Medovic M, Kralj D, Todorovic Z, Cekerevac M, Medovic R, Nikolic M. Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients. Int J Mol Sci. 2025;26:7274. https:\/\/doi.org\/10.3390\/ijms26157274.","journal-title":"Int J Mol Sci"},{"key":"791_CR22","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128:4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"key":"791_CR23","doi-asserted-by":"publisher","first-page":"e16205","DOI":"10.1111\/ene.16205","volume":"31","author":"AL Fisse","year":"2024","unstructured":"Fisse AL, Sch\u00e4fer E, Hieke A, Schr\u00f6der M, Klimas R, Br\u00fcnger J, Huckemann S, Gr\u00fcter T, Sgodzai M, Schneider-Gold C, Gold R, Nguyen HP, Pitarokoili K, Motte J, Arning L. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2024;31:e16205. https:\/\/doi.org\/10.1111\/ene.16205.","journal-title":"Eur J Neurol"},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4103\/jfmpc.jfmpc_1326_24","volume":"14","author":"A Kumar","year":"2025","unstructured":"Kumar A, Yendamuri S, Ahmad F, Mukherjee PB, Kumar R, Manrai M, Muthukrishnan J, Dawra S. Inflammatory biomarkers and adverse outcome in COVID-19: Prelude for future viral pandemics. J Family Med Prim Care. 2025;14:720\u20138. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1326_24.","journal-title":"J Family Med Prim Care"},{"key":"791_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Caba\u00f1as F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, W\u00e4hlby Hamr\u00e9n U, Leach A, Villafana T. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7:180\u20139. https:\/\/doi.org\/10.1016\/S2352-4642(22)00321-2.","journal-title":"Lancet Child Adolesc Health"},{"key":"791_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2567.2006.02408.x","volume":"119","author":"UJH Sachs","year":"2006","unstructured":"Sachs UJH, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor \u03b1-chain promoter. Immunology. 2006;119:83\u20139. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02408.x.","journal-title":"Immunology"},{"key":"791_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ibd\/izac188","volume":"29","author":"B Choi","year":"2023","unstructured":"Choi B, Sey M, Ponich T, Beaton M, Kim R, Wilson A. Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05 Genotype. Inflamm Bowel Dis. 2023;29:437\u201343. https:\/\/doi.org\/10.1093\/ibd\/izac188.","journal-title":"Inflamm Bowel Dis"},{"key":"791_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/nejmoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, deCamp AC, Rudnicki E, Huang Y, Gonzales P, Cabello R, Orrell C, Lama JR, Laher F, Lazarus EM, Sanchez J, Frank I, Hinojosa J, Sobieszczyk ME, Marshall KE, Mukwekwerere PG, Makhema J, Baden LR, Mullins JI, Williamson C, Hural J, McElrath MJ, Bentley C, Takuva S, Gomez Lorenzo MM, Burns DN, Espy N, Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Kublin JG, Gray G, Ledgerwood JE, Mascola JR, Cohen MS. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition, New England. J Med. 2021;384:1003\u201314. https:\/\/doi.org\/10.1056\/nejmoa2031738.","journal-title":"J Med"},{"key":"791_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/pr.2014.89","volume":"76","author":"KW Reisinger","year":"2014","unstructured":"Reisinger KW, Elst M, Derikx JPM, Nikkels PGJ, De Vries B, Adriaanse MPM, Jellema RK, Kramer BWW, Wolfs TGAM. Intestinal fatty acid-binding protein: A possible marker for gut maturation. Pediatr Res. 2014;76:261\u20138. https:\/\/doi.org\/10.1038\/pr.2014.89.","journal-title":"Pediatr Res"},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"e0135141","DOI":"10.1371\/journal.pone.0135141","volume":"10","author":"JE Mikulska","year":"2015","unstructured":"Mikulska JE. Analysis of Response Elements Involved in the Regulation of the Human Neonatal Fc Receptor Gene (FCGRT). PLoS ONE. 2015;10:e0135141. https:\/\/doi.org\/10.1371\/journal.pone.0135141.","journal-title":"PLoS ONE"},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"103203","DOI":"10.1016\/j.ebiom.2020.103203","volume":"64","author":"Y Huang","year":"2021","unstructured":"Huang Y, Naidoo L, Zhang L, Carpp L.N., Rudnicki E, Randhawa A, Gonzales P, McDermott A, Ledgerwood J, Lorenzo M.M.G., Burns D, DeCamp A, Juraska M, Mascola J, Edupuganti S, Mgodi N, Cohen M, Corey L, Andrew P, Karuna S, Gilbert P.B., Mngadi K, Lazarus E. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EBioMedicine. 2021;64:103203. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103203.","journal-title":"EBioMedicine"},{"key":"791_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf181","author":"S Mahomed","year":"2025","unstructured":"Mahomed S, Beliveau M, Heredia-Ortiz R, Osman F, Letsoalo M, Garrett N, Gengiah TN, Archary D, Wang J, Narpala S, Castro M, Serebryannyy L, Carlton K, Koup RA, Moore PL, Morris L, Abdool Karim Q. Abdool Karim, Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women. J Antimicrob Chemother. 2025. https:\/\/doi.org\/10.1093\/jac\/dkaf181.","journal-title":"J Antimicrob Chemother"},{"key":"791_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antib8040056","volume":"8","author":"VA Thomas","year":"2019","unstructured":"Thomas VA, Balthasar JP. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies. 2019;8:56. https:\/\/doi.org\/10.3390\/antib8040056.","journal-title":"Antibodies"},{"key":"791_CR34","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/bcp.13641","volume":"84","author":"C Li","year":"2018","unstructured":"Li C, Shoji S, Beebe J. Pharmacokinetics and C-reactive protein modelling of anti\u2010interleukin\u20106 antibody (PF\u201004236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol. 2018;84:2059\u201374. https:\/\/doi.org\/10.1111\/bcp.13641.","journal-title":"Br J Clin Pharmacol"},{"key":"791_CR35","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1111\/bcp.15339","volume":"88","author":"M Melhem","year":"2022","unstructured":"Melhem M, Hanze E, Lu S, Alsk\u00e4r O, Visser S, Gandhi Y. Population pharmacokinetics and exposure\u2013response of anti-programmed cell death protein\u20101 monoclonal antibody dostarlimab in advanced solid tumours. Br J Clin Pharmacol. 2022;88:4142\u201354. https:\/\/doi.org\/10.1111\/bcp.15339.","journal-title":"Br J Clin Pharmacol"},{"key":"791_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M, Li C, de Alwis D, de Greef R, Elassaiss-Schaap J, Kondic A, Stone J. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6:49\u201357. https:\/\/doi.org\/10.1002\/psp4.12139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"791_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41927-019-0079-2","volume":"3","author":"MJ Cuadrado","year":"2019","unstructured":"Cuadrado MJ, Calatayud I, Urquizu-Padilla M, Wijetilleka S, Kiani-Alikhan S, Karim MY. Immunoglobulin abnormalities are frequent in patients with lupus nephritis. BMC Rheumatol. 2019;3:30. https:\/\/doi.org\/10.1186\/s41927-019-0079-2.","journal-title":"BMC Rheumatol"},{"key":"791_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/337184a0","volume":"337","author":"NE Simister","year":"1989","unstructured":"Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337:184\u20137. https:\/\/doi.org\/10.1038\/337184a0.","journal-title":"Nature"},{"key":"791_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/372336a0","volume":"372","author":"WP Burmeister","year":"1994","unstructured":"Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 \u00c5 resolution of the MHC-related neonatal Fc receptor. Nature. 1994;372:336\u201343. https:\/\/doi.org\/10.1038\/372336a0.","journal-title":"Nature"},{"key":"791_CR40","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1242\/jcs.115.11.2389","volume":"115","author":"A Praetor","year":"2002","unstructured":"Praetor A, Hunziker W. \u03b22-microglobulin is important for cell surface expression and pH-dependent IgG binding of human FcRn. J Cell Sci. 2002;115:2389\u201397. https:\/\/doi.org\/10.1242\/jcs.115.11.2389.","journal-title":"J Cell Sci"},{"key":"791_CR41","doi-asserted-by":"publisher","unstructured":"Sand KMK, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and Albumin: Opportunities for design of albumin-based therapeutics. Front Immunol. 2015;5. https:\/\/doi.org\/10.3389\/fimmu.2014.00682.","DOI":"10.3389\/fimmu.2014.00682"},{"key":"791_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","volume":"39","author":"TT Gj\u00f8lberg","year":"2025","unstructured":"Gj\u00f8lberg T.T., Mester S, Calamera G, Telstad J.S., Sandlie I., Andersen J.T. Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress. BioDrugs. 2025;39:373\u2013409. https:\/\/doi.org\/10.1007\/s40259-025-00708-2.","journal-title":"BioDrugs"},{"key":"791_CR43","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1021\/bi052628y","volume":"45","author":"C Chaudhury","year":"2006","unstructured":"Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin Binding to FcRn: Distinct from the FcRn\u2009\u2013\u2009IgG Interaction. Biochemistry. 2006;45:4983\u201390. https:\/\/doi.org\/10.1021\/bi052628y.","journal-title":"Biochemistry"},{"key":"791_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1073\/pnas.0711515105","volume":"105","author":"S Akilesh","year":"2008","unstructured":"Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci. 2008;105:967\u201372. https:\/\/doi.org\/10.1073\/pnas.0711515105.","journal-title":"Proc Natl Acad Sci"},{"key":"791_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.20020400","volume":"196","author":"GM Spiekermann","year":"2002","unstructured":"Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196:303\u201310. https:\/\/doi.org\/10.1084\/jem.20020400.","journal-title":"J Exp Med"},{"key":"791_CR46","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1073\/pnas.1012861108","volume":"108","author":"Z Li","year":"2011","unstructured":"Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci. 2011;108:4388\u201393. https:\/\/doi.org\/10.1073\/pnas.1012861108.","journal-title":"Proc Natl Acad Sci"},{"key":"791_CR47","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol. 2015;194:4595\u2013603. https:\/\/doi.org\/10.4049\/jimmunol.1403014.","journal-title":"J Immunol"},{"key":"791_CR48","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1021\/bi000749m","volume":"39","author":"AP West","year":"2000","unstructured":"West AP, Bjorkman PJ. Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor. Biochemistry. 2000;39:9698\u2013708. https:\/\/doi.org\/10.1021\/bi000749m.","journal-title":"Biochemistry"},{"key":"791_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0969-2126(98)00008-2","volume":"6","author":"DE Vaughn","year":"1998","unstructured":"Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. 1998;6:63\u201373. https:\/\/doi.org\/10.1016\/S0969-2126(98)00008-2.","journal-title":"Structure"},{"key":"791_CR50","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","volume":"289","author":"V Oganesyan","year":"2014","unstructured":"Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H. Dall\u2019Acqua, Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms. J Biol Chem. 2014;289:7812\u201324. https:\/\/doi.org\/10.1074\/jbc.M113.537563.","journal-title":"J Biol Chem"},{"key":"791_CR51","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1091\/mbc.e04-08-0735","volume":"16","author":"ES Ward","year":"2005","unstructured":"Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From Sorting Endosomes to Exocytosis: Association of Rab4 and Rab11 GTPases with the Fc Receptor, FcRn, during Recycling. Mol Biol Cell. 2005;16:2028\u201338. https:\/\/doi.org\/10.1091\/mbc.e04-08-0735.","journal-title":"Mol Biol Cell"},{"key":"791_CR52","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra2312718","volume":"392","author":"JB Bussel","year":"2025","unstructured":"Bussel JB, Cines DB, Blumberg RS. Neonatal Fc Receptor \u2014 Biology and Therapeutics. N Engl J Med. 2025;392:1621\u201335. https:\/\/doi.org\/10.1056\/NEJMra2312718.","journal-title":"N Engl J Med"},{"key":"791_CR53","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","volume":"54","author":"S Ko","year":"2022","unstructured":"Ko S, Park S, Sohn MH, Jo M, Ko BJ, Na J-H, Yoo H, Jeong AL, Ha K, Woo JR, Lim C, Shin JH, Lee D, Choi S-Y, Jung ST. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies. Exp Mol Med. 2022;54:1850\u201361. https:\/\/doi.org\/10.1038\/s12276-022-00870-5.","journal-title":"Exp Mol Med"},{"key":"791_CR54","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","volume":"11","author":"BC Mackness","year":"2019","unstructured":"Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, Pasquier O, Schmidt T, Kabiri M, Kandira A, Rado\u0161evi\u0107 K, Qiu H. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs. 2019;11:1276\u201388. https:\/\/doi.org\/10.1080\/19420862.2019.1633883.","journal-title":"MAbs"},{"key":"791_CR55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146:467\u201378. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.015.","journal-title":"J Allergy Clin Immunol"},{"key":"791_CR56","doi-asserted-by":"publisher","unstructured":"Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presentation. Front Immunol. 2014;5. https:\/\/doi.org\/10.3389\/fimmu.2014.00408.","DOI":"10.3389\/fimmu.2014.00408"},{"key":"791_CR57","doi-asserted-by":"publisher","first-page":"112583","DOI":"10.1016\/j.intimp.2024.112583","volume":"138","author":"S Qian","year":"2024","unstructured":"Qian S, Zhang D, Yang Z, Li R, Zhang X, Gao F, Yu L. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention. Int Immunopharmacol. 2024;138:112583. https:\/\/doi.org\/10.1016\/j.intimp.2024.112583.","journal-title":"Int Immunopharmacol"},{"key":"791_CR58","doi-asserted-by":"publisher","first-page":"205031211987614","DOI":"10.1177\/2050312119876146","volume":"7","author":"MA Pab\u00f3n-Porras","year":"2019","unstructured":"Pab\u00f3n-Porras MA, Molina-R\u00edos S, Fl\u00f3rez-Su\u00e1rez JB, Coral-Alvarado PX, M\u00e9ndez-Patarroyo P. Quintana-L\u00f3pez, Rheumatoid arthritis and systemic lupus erythematosus: Pathophysiological mechanisms related to innate immune system. SAGE Open Med. 2019;7:2050312119876146. https:\/\/doi.org\/10.1177\/2050312119876146.","journal-title":"SAGE Open Med"},{"key":"791_CR59","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions. JAMA Intern Med. 2013;173:1416. https:\/\/doi.org\/10.1001\/jamainternmed.2013.7430.","journal-title":"JAMA Intern Med"},{"key":"791_CR60","doi-asserted-by":"publisher","unstructured":"Kroenke MA, Barger TE, Hu J, Miller MJ, Kalenian K, He L, Hsu H, Bartley Y, Chow VF-S, Teixeira MC, dos Santos BA, Sullivan LE, Cheng JR, Parnes R, Padaki S, Kuhns DT, Mytych. Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.782788.","DOI":"10.3389\/fimmu.2021.782788"},{"key":"791_CR61","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMra2033539","volume":"384","author":"P Cacoub","year":"2021","unstructured":"Cacoub P, Saadoun D. Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med. 2021;384:1038\u201352. https:\/\/doi.org\/10.1056\/NEJMra2033539.","journal-title":"N Engl J Med"},{"key":"791_CR62","doi-asserted-by":"publisher","unstructured":"Mikulska JE, Simister NE. Analysis of the promoter region of the human FcRn gene, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1492 (2000) 180\u20134. https:\/\/doi.org\/10.1016\/S0167-4781(00)00068-3","DOI":"10.1016\/S0167-4781(00)00068-3"},{"key":"791_CR63","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1101\/gad.2.4.383","volume":"2","author":"DE Levy","year":"1988","unstructured":"Levy DE, Kessler DS, Pine R, Reich N, Darnell JE. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 1988;2:383\u201393. https:\/\/doi.org\/10.1101\/gad.2.4.383.","journal-title":"Genes Dev"},{"key":"791_CR64","doi-asserted-by":"publisher","unstructured":"Su S, Liu Q, Zhang X, Wen X, Lei L, Shen F, Fan Z, Duo J, Lu Y, Di L, Wang M, Chen H, Zhu W, Xu M, Wang S, Da Y. VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis. Ther Adv Neurol Disord. 2021;14. https:\/\/doi.org\/10.1177\/1756286420986747.","DOI":"10.1177\/1756286420986747"},{"key":"791_CR65","doi-asserted-by":"publisher","unstructured":"Fisse AL, Sch\u00e4fer E, Hieke A, Schr\u00f6der M, Klimas R, Br\u00fcnger J, Huckemann S, Gr\u00fcter T, Sgodzai M, Schneider-Gold C, Gold R, Nguyen HP, Pitarokoili K, Motte J, Arning L. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2024;31. https:\/\/doi.org\/10.1111\/ene.16205.","DOI":"10.1111\/ene.16205"},{"key":"791_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1084\/jem.20021829","volume":"197","author":"C Chaudhury","year":"2003","unstructured":"Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL. The Major Histocompatibility Complex\u2013related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan. J Exp Med. 2003;197:315\u201322. https:\/\/doi.org\/10.1084\/jem.20021829.","journal-title":"J Exp Med"},{"key":"791_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.it.2006.05.004","volume":"27","author":"CL Anderson","year":"2006","unstructured":"Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective \u2013 FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27:343\u20138. https:\/\/doi.org\/10.1016\/j.it.2006.05.004.","journal-title":"Trends Immunol"},{"key":"791_CR68","doi-asserted-by":"publisher","unstructured":"Ward ES, Gelinas D, Dreesen E, Van Santbergen J, Andersen JT, Silvestri NJ, Kiss JE, Sleep D, Rader DJ, Kastelein JJP, Louagie E, Vidarsson G, Spriet I. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.892534.","DOI":"10.3389\/fimmu.2022.892534"},{"key":"791_CR69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. J Parenter Enter Nutr. 2019;43:181\u201393. https:\/\/doi.org\/10.1002\/jpen.1451.","journal-title":"J Parenter Enter Nutr"},{"key":"791_CR70","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5217\/ir.2022.00128","volume":"21","author":"P Kumar","year":"2023","unstructured":"Kumar P, Vuyyuru SK, Das P, Kante B, Ranjan MK, Thomas DM, Mundhra S, Sahu P, Venigalla PM, Jain S, Goyal S, Golla R, Virmani S, Singh MK, Sachdeva K, Sharma R, Dash NR, Makharia G, Kedia S, Ahuja V. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring. Intest Res. 2023;21:460\u201370. https:\/\/doi.org\/10.5217\/ir.2022.00128.","journal-title":"Intest Res"},{"key":"791_CR71","doi-asserted-by":"publisher","first-page":"e70185","DOI":"10.1002\/psp4.70185","volume":"15","author":"JR Proctor","year":"2026","unstructured":"Proctor JR, Wong H. Albumin Levels Are Predictive of Cachexia-Induced Time-Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab. CPT Pharmacometrics Syst Pharmacol. 2026;15:e70185. https:\/\/doi.org\/10.1002\/psp4.70185.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"791_CR72","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.ijo.0802718","volume":"28","author":"M Maachi","year":"2004","unstructured":"Maachi M, Pi\u00e9roni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard J-P. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF\u03b1, leptin and IL-6 levels in obese women. Int J Obes. 2004;28:993\u20137. https:\/\/doi.org\/10.1038\/sj.ijo.0802718.","journal-title":"Int J Obes"},{"key":"791_CR73","doi-asserted-by":"publisher","unstructured":"Zotova N, Zhuravleva Y, Chereshnev V, Gusev E. Acute and Chronic Systemic Inflammation: Features and Differences in the Pathogenesis, and Integral Criteria for Verification and Differentiation. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24021144.","DOI":"10.3390\/ijms24021144"},{"key":"791_CR74","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/oncotarget.23208","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9:7204\u201318. https:\/\/doi.org\/10.18632\/oncotarget.23208.","journal-title":"Oncotarget"},{"key":"791_CR75","doi-asserted-by":"publisher","unstructured":"Mwatelah R, McKinnon LR, Baxter C, Abdool Karim Q, Abdool Karim SS. Mechanisms of sexually transmitted infection-induced inflammation in women: implications for <\u2009scp>HIV risk. J Int AIDS Soc. 2019;22. https:\/\/doi.org\/10.1002\/jia2.25346.","DOI":"10.1002\/jia2.25346"},{"key":"791_CR76","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1038\/s41467-019-13089-2","volume":"10","author":"LJP Liebenberg","year":"2019","unstructured":"Liebenberg LJP, McKinnon LR, Yende-Zuma N, Garrett N, Baxter C, Kharsany ABM, Archary D, Rositch A, Samsunder N, Mansoor LE, Passmore J-AS, Abdool Karim SS. Abdool Karim, HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. Nat Commun. 2019;10:5227. https:\/\/doi.org\/10.1038\/s41467-019-13089-2.","journal-title":"Nat Commun"},{"key":"791_CR77","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s15010-023-01999-9","volume":"51","author":"A Franz","year":"2023","unstructured":"Franz A, Fuss A, Mazigo HD, Ruganuza D, M\u00fcller A. Prevalence of Schistosoma mansoni, soil-transmitted helminths and intestinal protozoa in orphans and street children in Mwanza city, Northern Tanzania. Infection. 2023;51:1399\u2013406. https:\/\/doi.org\/10.1007\/s15010-023-01999-9.","journal-title":"Infection"},{"key":"791_CR78","doi-asserted-by":"publisher","first-page":"4651891","DOI":"10.1155\/2021\/4651891","volume":"2021","author":"RP Santiago","year":"2021","unstructured":"Santiago RP, Carvalho MOS, Figueiredo CVB, Fiuza LM, Oliveira RM, Yahou\u00e9d\u00e9hou SCMA, Nascimento VML, Lyra IM, Araujo-Santos T, Luz NF, Aleluia MM, Guarda CC, Borges VM, Goncalves MS. Associations between TGF-\u03b21 Levels and Markers of Hemolysis, Inflammation, and Tissue Remodeling in Pediatric Sickle Cell Patients. Mediators Inflamm. 2021;2021:4651891. https:\/\/doi.org\/10.1155\/2021\/4651891.","journal-title":"Mediators Inflamm"},{"key":"791_CR79","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.3390\/ijms22137216","volume":"22","author":"P Masamba","year":"2021","unstructured":"Masamba P, Kappo AP. Immunological and Biochemical Interplay between Cytokines, Oxidative Stress and Schistosomiasis. Int J Mol Sci. 2021;22:7216. https:\/\/doi.org\/10.3390\/ijms22137216.","journal-title":"Int J Mol Sci"},{"key":"791_CR80","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1365-2567.1996.d01-775.x","volume":"89","author":"EJ ISRAEL","year":"1996","unstructured":"ISRAEL EJ, WILSKER DF, HAYES KC, SCHOENFELD D, SIMISTER NE. Increased clearance of IgG in mice that lack \u03b2-microglobulin: possible protective role of FcRn. Immunology. 1996;89:573\u20138. https:\/\/doi.org\/10.1046\/j.1365-2567.1996.d01-775.x.","journal-title":"Immunology"},{"key":"791_CR81","doi-asserted-by":"publisher","unstructured":"Sinkala E, Ahmed HY, Sibomana JP, Lee MH, Kassa B, Kumar R, Mazimba S, Binegdie AB, Mpisa S, Wamundila K, Graham BB, Hilton JF. Rationale and design of a screening study to detect schistosomiasis-associated pulmonary hypertension in Ethiopia and Zambia. Pulm Circ. 2022;12. https:\/\/doi.org\/10.1002\/pul2.12072.","DOI":"10.1002\/pul2.12072"},{"key":"791_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","volume":"19","author":"S Ko","year":"2025","unstructured":"Ko S, Jo M, Kyung M, Lee W, Ko WH, Na J-H, Chun YS, Ko BJ, Jung ST. Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential. J Biol Eng. 2025;19:35. https:\/\/doi.org\/10.1186\/s13036-025-00506-y.","journal-title":"J Biol Eng"},{"key":"791_CR83","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1242\/jcs.113.7.1277","volume":"113","author":"KM McCarthy","year":"2000","unstructured":"McCarthy KM, Yoong Y, Simister NE. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J Cell Sci. 2000;113:1277\u201385. https:\/\/doi.org\/10.1242\/jcs.113.7.1277.","journal-title":"J Cell Sci"},{"key":"791_CR84","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ncomms1608","volume":"2","author":"NM Stapleton","year":"2011","unstructured":"Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2:599. https:\/\/doi.org\/10.1038\/ncomms1608.","journal-title":"Nat Commun"},{"key":"791_CR85","doi-asserted-by":"publisher","unstructured":"Haraya K, Ichikawa T, Murao N, Katada H, Kuramochi T. Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice. MAbs. 2025;17. https:\/\/doi.org\/10.1080\/19420862.2025.2484443.","DOI":"10.1080\/19420862.2025.2484443"},{"key":"791_CR86","first-page":"211","volume":"12","author":"J Kekow","year":"1988","unstructured":"Kekow J, Hobusch G, Gross WL. Predominance of the IgG1 subclass in the hypergammaglobulinemia observed in pre-AIDS and AIDS. Cancer Detect Prev. 1988;12:211\u20136.","journal-title":"Cancer Detect Prev"},{"key":"791_CR87","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","volume":"24","author":"AW Weflen","year":"2013","unstructured":"Weflen AW, Baier N, Tang Q-J, Van den Hof M, Blumberg RS, Lencer WI, Massol RH. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell. 2013;24:2398\u2013405. https:\/\/doi.org\/10.1091\/mbc.e13-04-0174.","journal-title":"Mol Biol Cell"},{"key":"791_CR88","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1073\/pnas.0801717105","volume":"105","author":"S-W Qiao","year":"2008","unstructured":"Qiao S-W, Kobayashi K, Johansen F-E, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Nat Acad Sci. 2008;105:9337\u201342. . https:\/\/doi.org\/10.1073\/pnas.0801717105","journal-title":"Proc Nat Acad Sci"},{"key":"791_CR89","doi-asserted-by":"publisher","unstructured":"Werner A, Hani\u0107 M, Zaitseva OO, Lauc G, Lux A, Nitschke L, Nimmerjahn F. IgG sialylation occurs in B cells pre antibody secretion. Front Immunol. 2024;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1402000.","DOI":"10.3389\/fimmu.2024.1402000"},{"key":"791_CR90","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/S0140-6736(87)92621-3","volume":"330","author":"J Axford","year":"1987","unstructured":"Axford J, Lydyard P, Isenberg D, Mackenzie L, Hay F, Roitt I. Reduced, B-CELL Galactosyltransferase, activity in rheumatoid arthritis. Lancet. 1987;330:1486\u20138. . https:\/\/doi.org\/10.1016\/S0140-6736(87)92621-3","journal-title":"Lancet"},{"key":"791_CR91","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2017.00646","volume":"8","author":"B Peschke","year":"2017","unstructured":"Peschke B, Keller CW, Weber P, Quast I, L\u00fcnemann JD. Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity. Front Immunol. 2017;8:646. https:\/\/doi.org\/10.3389\/fimmu.2017.00646.","journal-title":"Front Immunol"},{"key":"791_CR92","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3109\/07853899609033129","volume":"28","author":"JK Lacki","year":"1996","unstructured":"Lacki JK, Porawska W, Mackiewicz U, Mackiewicz S. Changes in Agalactosyl IgG Levels Correlate with Radiological Progression in Early Rheumatoid Arthritis. Ann Med. 1996;28:265\u20139. https:\/\/doi.org\/10.3109\/07853899609033129.","journal-title":"Ann Med"},{"key":"791_CR93","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10067-006-0370-7","volume":"26","author":"E Gindzienska-Sieskiewicz","year":"2007","unstructured":"Gindzienska-Sieskiewicz E, Klimiuk PA, Kisiel DG, Gindzienski A, Sierakowski S. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis. Clin Rheumatol. 2007;26:685\u201390. https:\/\/doi.org\/10.1007\/s10067-006-0370-7.","journal-title":"Clin Rheumatol"},{"key":"791_CR94","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1021\/pr400589m","volume":"12","author":"A Bondt","year":"2013","unstructured":"Bondt A, Selman MHJ, Deelder AM, Hazes JMW, Willemsen SP, Wuhrer M, Dolhain RJEM. Association between Galactosylation of Immunoglobulin G and Improvement of Rheumatoid Arthritis during Pregnancy Is Independent of Sialylation. J Proteome Res. 2013;12:4522\u201331. https:\/\/doi.org\/10.1021\/pr400589m.","journal-title":"J Proteome Res"},{"key":"791_CR95","doi-asserted-by":"publisher","unstructured":"Wilcox CR, Holder B, Jones CE. Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy. Front Immunol. 2017;8. https:\/\/doi.org\/10.3389\/fimmu.2017.01294.","DOI":"10.3389\/fimmu.2017.01294"},{"key":"791_CR96","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23:415\u201332. https:\/\/doi.org\/10.1038\/s41577-022-00821-1.","journal-title":"Nat Rev Immunol"},{"key":"791_CR97","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/infdis\/jis524","volume":"208","author":"CD Bourke","year":"2013","unstructured":"Bourke CD, Nausch N, Rujeni N, Appleby LJ, Mitchell KM, Midzi N, Mduluza T, Mutapi F. Integrated Analysis of Innate, Th1, Th2, Th17, and Regulatory Cytokines Identifies Changes in Immune Polarisation Following Treatment of Human Schistosomiasis. J Infect Dis. 2013;208:159\u201369. https:\/\/doi.org\/10.1093\/infdis\/jis524.","journal-title":"J Infect Dis"},{"key":"791_CR98","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bbrc.2003.09.168","volume":"311","author":"H-J Kwon","year":"2003","unstructured":"Kwon H-J, Lee K-W, Ho Yu S, Ho Han J, Kim D-S. NF-\u03baB-dependent regulation of tumor necrosis factor-\u03b1 gene expression by CpG-oligodeoxynucleotides. Biochem Biophys Res Commun. 2003;311:129\u201338. https:\/\/doi.org\/10.1016\/j.bbrc.2003.09.168.","journal-title":"Biochem Biophys Res Commun"},{"key":"791_CR99","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bjo.2010.187930","volume":"95","author":"K van Bilsen","year":"2011","unstructured":"van Bilsen K, van Hagen PM, Bastiaans J, van Meurs JC, Missotten T, Kuijpers RW, Hooijkaas H, Dingjan GM, Baarsma GS, Dik WA. The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha. Br J Ophthalmol. 2011;95:864\u20138. https:\/\/doi.org\/10.1136\/bjo.2010.187930.","journal-title":"Br J Ophthalmol"},{"key":"791_CR100","doi-asserted-by":"publisher","unstructured":"Jalbert E, Williamson KM, Kroehl ME, Johnson MJ, Cutland C, Madhi SA, Nunes MC, Weinberg A. HIV-exposed uninfected infants have increased regulatory T Cells that correlate with decreased T Cell function. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.00595.","DOI":"10.3389\/fimmu.2019.00595"},{"key":"791_CR101","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.xphs.2025.103904","volume":"114","author":"X Cai","year":"2025","unstructured":"Cai X, Wu W, Xu J, Lin W, Huang P, Lin C, Lin R. Physiologically based pharmacokinetic model of IgG to predict mother-to-fetus transfer of ustekinumab in pregnant patients with inflammatory bowel disease. J Pharm Sci. 2025;114:103904. https:\/\/doi.org\/10.1016\/j.xphs.2025.103904.","journal-title":"J Pharm Sci"},{"key":"791_CR102","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/cpt.3656","volume":"118","author":"MS Kardouh","year":"2025","unstructured":"Kardouh MS, Dunlap TC, Zhong R, Tiley JB, Cao Y. Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model. Clin Pharmacol Ther. 2025;118:394\u2013407. https:\/\/doi.org\/10.1002\/cpt.3656.","journal-title":"Clin Pharmacol Ther"},{"key":"791_CR103","doi-asserted-by":"publisher","unstructured":"Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling, MAbs. 2018:1\u201313. https:\/\/doi.org\/10.1080\/19420862.2018.1494479","DOI":"10.1080\/19420862.2018.1494479"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00791-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:01:37Z","timestamp":1783666897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00791-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00791-2","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"23"}}